GSK’s Stiefel to acquire psoriasis, eczema compound from Welichem
GlaxoSmithKline‘s (NYSE:GSK) dermatology subsidiary Stiefel is building up its drug pipeline with a deal in principal to acquire a skin treatment candidate from Welichem Biotech (TSX:WBI). Stiefel gets development and commercialization rights to anti-inflammatory compound WBI-1001, which is currently in phase 2 clinical development for treating psoriasis and atopic dermatitis, a type of eczema. The […]